Department of Anesthesiology, Mayo Clinic, Rochester, MN 55905, USA.
Reg Anesth Pain Med. 2012 Mar-Apr;37(2):139-44. doi: 10.1097/AAP.0b013e318244179a.
Recent reports of infectious complications after neuraxial procedures highlight the importance of scrupulous aseptic technique. Although chlorhexidine gluconate (CHG) has several advantages over other antiseptic agents; including a more rapid onset of action, an extended duration of effect, and rare bacterial resistance, it is not approved by the US Food and Drug Administration for use before lumbar puncture because of absence of clinical safety evidence. The objective of this retrospective cohort study was to test the hypothesis that the incidence of neurologic complications associated with spinal anesthesia after CHG skin antisepsis is not different than the known incidence of neurologic complications associated with spinal anesthesia.
All patients 18 years or older who underwent spinal anesthesia at Mayo Clinic Rochester from 2006 to 2010 were identified. The primary outcome variable was the presence of any new or progressive neurologic deficit documented within 7 days of spinal anesthesia. The etiology of a patient's neurologic complication was independently categorized as possibly or unlikely related to the spinal anesthetic by 3 investigators. Consensus among all reviewers was required for final category assignment.
A total of 11,095 patients received 12,465 spinal anesthetics during the study period. Overall, 57 cases (0.46%; 95% confidence interval, 0.34%-0.58%) met criteria for neurologic complication. Spinal anesthesia was felt to be the possible etiology of 5 neurologic complications (0.04%; 95% confidence interval, 0.00%-0.08%); all completely resolved within 30 days.
The incidence of neurologic complications possibly associated with spinal anesthesia (0.04%) after CHG skin antisepsis is consistent with previous reports of neurologic complications after spinal anesthesia. These results support the hypothesis that CHG can be used for skin antisepsis before spinal placement without increasing the risk of neurologic complications attributed to the spinal anesthetic.
最近有关神经轴突手术后感染并发症的报道强调了严格无菌技术的重要性。虽然洗必泰葡萄糖酸(CHG)相对于其他消毒剂具有许多优势,包括起效更快、作用持续时间更长以及罕见的细菌耐药性,但由于缺乏临床安全性证据,美国食品和药物管理局尚未批准其用于腰椎穿刺前。本回顾性队列研究的目的是检验以下假设,即使用 CHG 皮肤消毒后行脊髓麻醉相关的神经并发症发生率与已知的脊髓麻醉相关神经并发症发生率没有差异。
本研究纳入了 2006 年至 2010 年在梅奥诊所罗切斯特院区接受脊髓麻醉的所有 18 岁及以上的患者。主要结局变量为脊髓麻醉后 7 天内记录到的任何新发或进行性神经功能缺损。3 名研究者将患者的神经并发症病因独立归类为可能或不太可能与脊髓麻醉相关。只有在所有审查者达成一致意见的情况下,最终才会确定分类。
研究期间共有 11095 例患者接受了 12465 次脊髓麻醉。总体而言,57 例(0.46%;95%置信区间,0.34%-0.58%)符合神经并发症标准。5 例神经并发症(0.04%;95%置信区间,0.00%-0.08%)被认为可能是脊髓麻醉引起的,所有患者均在 30 天内完全恢复。
在使用 CHG 皮肤消毒后,与脊髓麻醉相关的神经并发症发生率(0.04%)与先前报道的脊髓麻醉后神经并发症发生率一致。这些结果支持以下假设,即 CHG 可用于脊髓穿刺前的皮肤消毒,而不会增加归因于脊髓麻醉的神经并发症风险。